Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totaling 30,190 shares, a growth of 440.0% from the September 30th total of 5,591 shares. Based on an average trading volume of 39,784 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.7% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
View Our Latest Analysis on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Trading Down 5.0%
NASDAQ:BGMS traded down $0.05 during trading hours on Thursday, reaching $0.87. The company had a trading volume of 10,399 shares, compared to its average volume of 757,540. The firm has a market cap of $4.82 million, a price-to-earnings ratio of -0.24 and a beta of -0.39. The firm’s 50 day moving average price is $0.90 and its 200-day moving average price is $0.97. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.80.
Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%. The firm had revenue of $0.34 million during the quarter.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options.
The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.
See Also
- Five stocks we like better than Cyclacel Pharmaceuticals
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
